ÖZLEM TERZİ

Dr. ÖZLEM TERZİ

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
ÖTÖZLEM TERZİ
ÖZLEM TERZİ
SHSadik Sami Hatipoğlu
Sadik Sami Hatipoğlu
Background: Rare factor deficiency (RFD) is characterized by a deficiency of factor (F)I, FII, FV, FVII, FX, FXI, FXII, FXIII, or a combined deficiency of FV+FVIII or vitamin K-dependent factors. The prevalence of RFD ranges from 1/1,000,000 to 3,000,000. Combined deficiencies of vitamin K-related factors have been described in 30 families worldwide, and these patients can present with a wide range of clinical symptoms, from mucocutaneous bleeding to life-threatening symptoms such as central nervous system and gastrointestinal bleeding. Objective: This study aimed to contribute to the literature on RFD. Material and Methods: This retrospective study analyzed data from 43 children with RFD. Results: The most common factor deficiencies were FVII (n=13); whereas the other deficiencies were FI (n=1), FV (n=2), FV+FVIII (n=2), FX (n=6), FXI (n=5), FXII (n=9), FXIII (n=3), and vitamin K-dependent combined factor deficiency (n=2). Acute and severe bleeding was controlled by treatment in 6 patients, and 12 patients with recurrent bleeding symptoms received prophylaxis. RFDs were more common in regions with high rates of consanguineous marriage, and in our study, 16 (16/43) of the cases were found to have consanguineous marriages between parents. Conclusions: It is important to improve genetic counseling and access to testing for family members with RFD due to autosomal recessive inheritance. Delays in diagnosis and treatment and lack of adequate prevention are important risk factors for life-threatening bleeding.

23 June 2023 in Medical Bulletin of Haseki
Verified
Journal Article
Closed access
HSHuseyin Avni Solgun
Huseyin Avni Solgun
SASeyma Acikgoz
Seyma Acikgoz
DYDuygu Ozkorucu Yildirgan
Duygu Ozkorucu Yildirgan
ÖTÖZLEM TERZİ
ÖZLEM TERZİ
AAAli Aycicek
Ali Aycicek

6 September 2023 in Online Türk Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
ÖTÖZLEM TERZİ
ÖZLEM TERZİ
Objective: The prevalence of rare factor deficiency (RFD) is one in 500.000-2.000.000 in the general population. Different symptoms may occur from mild or moderate bleeding to severe and life-threatening bleeding. This study aimed to evaluate children with RFD in a single Turkish center. Materials and Methods: The records of children with RFD (Factor I, V, VII, X, XIII deficiency) were evaluated retrospectively. Results: Twenty-three cases (70% female) were reviewed. The mean age of patients was 9.52 years at review, and mean follow-up was 66.3 months. The most common factor (F) deficiencies were FVII (35%) and FX (35%). Parental consanguinity was present in 65%. The most common symptoms were mucocutaneous bleeding and epistaxis. Regarding treatment, fresh frozen plasma (FFP) was given to two patients, FXIII concentrate was given to one patient, and prothrombin complex concentrate (PCC) was given to two patients. Prophylaxis was started in patients with recurrent bleeding. Of the 16 receiving prophylaxis, three received FFP, seven received recombinant coagulation factor VIIa, and six received PCC. Conclusion: Treatment was given to a fifth of patients while nearly three-quarters received prophylaxis. As parental consanguinity was present in most of these patients, obtaining a detailed family history may aid in diagnosis.

28 November 2022 in Medical Laboratory Technology Journal
Verified
Journal Article
Open access
PDF file
ÖTÖZLEM TERZİ
ÖZLEM TERZİ
CBCengiz Bayram
Cengiz Bayram
AAAli Ayçiçek
Ali Ayçiçek
EUEzgi Uysalol
Ezgi Uysalol
CBCennet Nur Baş
Cennet Nur Baş
STSibel Tekgündüz
Sibel Tekgündüz
The prognostic value of thrombocytosis and inflammatory biomarkers in adult cancer patients has been the subject of many studies. This study investigated the role of platelet count and other inflammatory biomarkers in the prognosis of solid childhood tumours. The data of 176 pediatric patients diagnosed with solid tumours were evaluated retrospectively; 150 patients still under follow-up were included in the study. We examined the relationship between platelet count, platelet/neutrophil ratio (PNR), platelet/lymphocyte ratio (PLR) and platelet/monocyte ratio (PMR) at the time of diagnosis on survival. The mean age of diagnosis was 7.91 ± 5.75 years, and 60.7% were male. The mean platelet count of the patients was 424.326 ± 167197.32. The median (range) follow-up was 13 (1-68) months. Relapse was seen in 18% of the patients, and 9.3% died. The relationship between PMR and overall survival (OS) and event-free survival times (EFS) was statistically significant (p=0.002 and p=0.016, respectively). However, no statistically significant association was found for PLR or PNR. Overall survival and EFS were significantly poorer in this cohort in patients with high pretreatment PMR.

28 September 2024 in Iranian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ÖTÖZLEM TERZİ
ÖZLEM TERZİ
AAAli Aycicek
Ali Aycicek
EUEzgi Pasli Uysalol
Ezgi Pasli Uysalol
SESaide Erturk
Saide Erturk
OHOzgu Hancerli
Ozgu Hancerli
CBCengiz Bayram
Cengiz Bayram
Background: Hyperleukocytosis (HL) in pediatric acute leukemia is associated with increased morbidity and mortality. The indications for leukapheresis (LPH) in these patients remain unclear, and the use of LPH remains controversial. Objectives: This study aimed to review the clinical characteristics and outcomes of newly diagnosed leukemia patients with HL, comparing those who received LPH and those who did not. Methods: We analyzed clinical data from patients enrolled in frontline protocols for acute leukemia between 2017 and 2022. We documented adverse events within the first 30 days in patients with a white blood cell (WBC) count ≥ 100,000 cells/mm³ and reviewed their management. Treatment strategies included hyperhydration, administration of allopurinol or rasburicase, early induction chemotherapy (CT), and LPH. Results: Of 404 pediatric patients with newly diagnosed acute leukemia, 41 (10.1%) presented with HL (median WBC count: 136,000 cells/mm³; range HL: 101,000 - 844,000 cells/mm³). Leukapheresis was used in 9 of the 41 (13%) patients with HL. The median WBC count in patients who received LPH was 520,000 cells/mm³ compared to 158,800 cells/mm³ in those who did not (P = 0.01). Pulmonary leukostasis occurred in 2 patients, one of whom underwent LPH. No early deaths related to cerebral leukostasis, coagulopathy, or pulmonary leukostasis were observed in any patient within the first 30 days. The LPH procedure was well tolerated, with no reported complications. The time from presentation to the initiation of CT was similar between patients who received LPH and those who did not, with a mean of 17 hours versus 18 hours, respectively (P > 0.05). Tumor lysis syndrome (clinical or laboratory) was observed in 2 patients (23%) with LPH and 2 patients (6.25%) without LPH. Conclusions: The early morbidity and mortality often associated with HL in children with newly diagnosed acute leukemia can be avoided through conservative management, potentially reducing the need for LPH. However, LPH is a safe and well-tolerated procedure at our institution. It may be considered for patients with leukostasis when early induction CT is not feasible.

1 January 2022 in Eurasian Journal of Medical Advances
Verified
Journal Article
Closed access
ÖTÖZLEM TERZİ
ÖZLEM TERZİ
HSHüseyin Avni Solğun
Hüseyin Avni Solğun
SDSümeyra Doğan
Sümeyra Doğan
STSibel Akpınar Tekgündüz
Sibel Akpınar Tekgündüz
AAAli Ayçiçek
Ali Ayçiçek
Infantile Hepatic Hemangioendothelioma (IHH) is an extremely rare and painless vascular tumor. IHH is usually in benign nature but it can also be life-threatening with a rapid growth tendency. There are approaches in the treatment of IHH, ranging from drug therapy to liver transplantation. Propranolol, which is used in first-line therapy for most patients, is effective alone in the treatment.